| Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (NCT04427072) | Novartis Pharmaceuticals | 2020-09-25 |
| Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML) (NCT05488613) | Novartis Pharmaceuticals | 2020-09-24 |
| Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants (NCT04564053) | Novartis Pharmaceuticals | 2020-09-23 |
| Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis (NCT04064242) | Novartis Pharmaceuticals | 2020-09-23 |
| Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT04268823) | Novartis Pharmaceuticals | 2020-09-10 |
| Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma (NCT04410523) | Novartis Pharmaceuticals | 2020-09-09 |
| Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (NCT04240704) | Novartis Pharmaceuticals | 2020-09-07 |
| A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy (NCT04150029) | Novartis Pharmaceuticals | 2020-09-01 |
| Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims Data (NCT05177406) | Novartis Pharmaceuticals | 2020-08-31 |
| Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD) (NCT04443907) | Novartis Pharmaceuticals | 2020-08-25 |
| A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC (NCT04452877) | Novartis Pharmaceuticals | 2020-08-19 |
| Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations (NCT04323436) | Novartis Pharmaceuticals | 2020-08-19 |
| Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL) (NCT05366257) | Novartis Pharmaceuticals | 2020-08-17 |
| Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program (NCT05066685) | Novartis Pharmaceuticals | 2020-08-11 |
| Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria (NCT04513548) | Novartis Pharmaceuticals | 2020-08-05 |
| Safety, Tolerability, and Pharmacokinetics of XXB750 in Healthy Participants (NCT06558097) | Novartis Pharmaceuticals | 2020-07-29 |
| PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus (NCT04300296) | Novartis Pharmaceuticals | 2020-07-27 |
| BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma (NCT04318327) | Novartis Pharmaceuticals | 2020-07-23 |
| A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer (NCT04294160) | Novartis Pharmaceuticals | 2020-07-22 |
| Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects (NCT04321252) | Novartis Pharmaceuticals | 2020-07-22 |
| Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA (NCT04097379) | Novartis Pharmaceuticals | 2020-07-20 |
| Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation (NCT04208178) | Novartis Pharmaceuticals | 2020-07-16 |
| Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry) (NCT05110209) | Novartis Pharmaceuticals | 2020-07-15 |
| Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health) (NCT05146687) | Novartis Pharmaceuticals | 2020-07-15 |
| An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab (NCT04353492) | Novartis Pharmaceuticals | 2020-07-14 |
| Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo (NCT05826028) | Novartis Pharmaceuticals | 2020-07-09 |
| Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis (NCT05344482) | Novartis Pharmaceuticals | 2020-07-09 |
| Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis (NCT04181762) | Novartis Pharmaceuticals | 2020-07-07 |
| Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities. (NCT05375097) | Novartis Pharmaceuticals | 2020-07-03 |
| Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France (NCT05964946) | Novartis Pharmaceuticals | 2020-06-24 |
| Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health) (NCT05111743) | Novartis Pharmaceuticals | 2020-06-17 |
| Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden (NCT05611229) | Novartis Pharmaceuticals | 2020-06-16 |
| Study of Efficacy and Safety of MAS825 in Patients With COVID-19 (NCT04382651) | Novartis Pharmaceuticals | 2020-06-11 |
| Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib (NCT04285723) | Novartis Pharmaceuticals | 2020-06-09 |
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (NCT04266301) | Novartis Pharmaceuticals | 2020-06-08 |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (NCT04251533) | Novartis Pharmaceuticals | 2020-06-08 |
| Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia (NCT03628053) | Novartis Pharmaceuticals | 2020-06-05 |
| Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH) (NCT04147195) | Novartis Pharmaceuticals | 2020-06-04 |
| A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data (NCT05096143) | Novartis Pharmaceuticals | 2020-06-03 |
| Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study) (NCT05082415) | Novartis Pharmaceuticals | 2020-06-03 |
| The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor. (NCT04408937) | Novartis Pharmaceuticals | 2020-05-29 |
| Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia (NCT04382053) | Novartis Pharmaceuticals | 2020-05-27 |
| Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant (NCT03774082) | Novartis Pharmaceuticals | 2020-05-20 |
| Impact of Fingolimod Adherence on Outcomes (NCT05141669) | Novartis Pharmaceuticals | 2020-05-18 |
| Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors (NCT05153135) | Novartis Pharmaceuticals | 2020-05-08 |
| Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (NCT04362137) | Novartis Pharmaceuticals | 2020-05-02 |
| Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease (NCT04358081) | Novartis Pharmaceuticals | 2020-05-01 |
| Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia (NCT04362813) | Novartis Pharmaceuticals | 2020-04-30 |
| A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors (NCT05141240) | Novartis Pharmaceuticals | 2020-04-15 |
| Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models (NCT05096039) | Novartis Pharmaceuticals | 2020-04-10 |
| Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab (NCT04210843) | Novartis Pharmaceuticals | 2020-04-08 |
| Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa (NCT04179175) | Novartis Pharmaceuticals | 2020-03-18 |
| Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab (NCT05037396) | Novartis Pharmaceuticals | 2020-03-05 |
| XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States (NCT05157087) | Novartis Pharmaceuticals | 2020-03-01 |
| A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab (NCT04261439) | Novartis Pharmaceuticals | 2020-02-27 |
| A First-in-Human Study of CEE321 in Adult Subjects (NCT04612062) | Novartis Pharmaceuticals | 2020-02-27 |
| KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (NCT04237649) | Novartis Pharmaceuticals | 2020-02-20 |
| A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD) (NCT04237116) | Novartis Pharmaceuticals | 2020-02-19 |
| Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis (NCT04074590) | Novartis Pharmaceuticals | 2020-02-03 |
| Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel (NCT05541328) | Novartis Pharmaceuticals | 2020-02-03 |
| Heart Failure IDentification in a High Risk Cardiovascular OutpatiEnt Population (HIDE) (NCT04143919) | Novartis Pharmaceuticals | 2020-01-31 |
| Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis (NCT04209205) | Novartis Pharmaceuticals | 2020-01-29 |
| Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% (NCT04139317) | Novartis Pharmaceuticals | 2020-01-22 |
| Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy (NCT04164732) | Novartis Pharmaceuticals | 2020-01-08 |
| Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis. (NCT04065841) | Novartis Pharmaceuticals | 2019-12-30 |
| Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients (NCT04066244) | Novartis Pharmaceuticals | 2019-12-30 |
| Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD (NCT04023552) | Novartis Pharmaceuticals | 2019-12-12 |
| Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA (NCT04156620) | Novartis Pharmaceuticals | 2019-12-11 |
| Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease (NCT04053764) | Novartis Pharmaceuticals | 2019-12-10 |
| Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC (NCT04023227) | Novartis Pharmaceuticals | 2019-12-10 |
| Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects. (NCT03988608) | Novartis Pharmaceuticals | 2019-12-09 |
| A Study of WVT078 in Patients With Multiple Myeloma (MM) (NCT04123418) | Novartis Pharmaceuticals | 2019-12-05 |
| Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration (NCT04047472) | Novartis Pharmaceuticals | 2019-11-29 |
| Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy (NCT04154787) | Novartis Pharmaceuticals | 2019-11-23 |
| Study of Out of Specification for Tisagenlecleucel (NCT04094311) | Novartis Pharmaceuticals | 2019-11-21 |
| HDM201 Added to CT in R/R or Newly Diagnosed AML (NCT03760445) | Novartis Pharmaceuticals | 2019-11-15 |
| Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects (NCT04129528) | Novartis Pharmaceuticals | 2019-11-08 |
| This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (NCT03968419) | Novartis Pharmaceuticals | 2019-11-05 |
| Pediatric Long-Term Follow-up and Rollover Study (NCT03975829) | Novartis Pharmaceuticals | 2019-11-04 |
| Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments (NCT04058756) | Novartis Pharmaceuticals | 2019-10-30 |
| Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab (NCT04114630) | Novartis Pharmaceuticals | 2019-10-30 |
| An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU (NCT04109313) | Novartis Pharmaceuticals | 2019-10-24 |
| A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism (NCT03938454) | Novartis Pharmaceuticals | 2019-10-16 |
| Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma. (NCT03989635) | Novartis Pharmaceuticals | 2019-10-15 |
| Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension (NCT03781414) | Novartis Pharmaceuticals | 2019-10-07 |
| Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN (NCT03955445) | Novartis Pharmaceuticals | 2019-10-03 |
| Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome (NCT03905525) | Novartis Pharmaceuticals | 2019-10-01 |
| Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study (NCT04084314) | Novartis Pharmaceuticals | 2019-09-30 |
| Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (NCT04097821) | Novartis Pharmaceuticals | 2019-09-26 |
| Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) (NCT04005352) | Novartis Pharmaceuticals | 2019-09-25 |
| A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas (NCT04104776) | Novartis Pharmaceuticals | 2019-09-18 |
| Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients (NCT04072887) | Novartis Pharmaceuticals | 2019-09-12 |
| Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients (NCT03867201) | Novartis Pharmaceuticals | 2019-08-26 |
| To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema (NCT04058067) | Novartis Pharmaceuticals | 2019-08-23 |
| A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients (NCT03977649) | Novartis Pharmaceuticals | 2019-07-30 |
| Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (NCT04000529) | Novartis Pharmaceuticals | 2019-07-30 |
| Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients (NCT03814746) | Novartis Pharmaceuticals | 2019-07-26 |
| Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients (NCT03944707) | Novartis Pharmaceuticals | 2019-07-18 |
| Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (NCT03917472) | Novartis Pharmaceuticals | 2019-07-17 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome (NCT04035668) | Novartis Pharmaceuticals | 2019-07-12 |